Cointime update: Eli Lilly said its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the primary goal of a late-stage clinical trial. At week 52, Foundayo cut breathing interruptions by up to 44% on average, as measured by the diagnostic scale used to assess sleep apnea severity. Obstructive sleep apnea is a disorder in which the upper airway repeatedly collapses during sleep, lowering blood oxygen and disrupting breathing.
Eli Lilly’s Foundayo Meets Primary Endpoint in Late-Stage Sleep Apnea Trial
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
CoinShares Q3 AUM Rebounds to $7.4B, Turns Profit; Board Approves Up to $40M Buyback
1h ago
Goldman Sachs’ Ethereum ETF Holdings Rise to $1.22B in Q3, ETHA Stake Up 352%
2h ago
Charles Schwab Adds 749,566 Strive Shares Worth $77.2M
2h ago
US Compute-Cloud Stocks Rise in Pre-Market Trading
2h ago
Nvidia shares rise 3% premarket on stronger-than-expected Q4 revenue forecast
2h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027